FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Merck & Belsomra Recall

Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Bli…

Merck & Co. Inc · Rahway, NJ

Risk level
Class II
Reported by FDA
Aug 20, 2025
Recall ID
D-0584-2025
Check your lot numberHow we source this data

Summary

Merck & recalled Belsomra starting Jul 21, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0584-2025 on Aug 20, 2025. Reason: Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep. Status: Ongoing.

Why it was recalled

Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.

Product description

Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label)

Lot numbers, UPCs & expiration codes

Lots 2090019 and 2123744, Exp. 4/30/2027

Where it was sold

Nationwide in the USA and PR.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0584-2025
Classification
Class II
Status
Ongoing
Recall initiated
Jul 21, 2025
FDA report date
Aug 20, 2025
Quantity
51,320 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Merck & Co. Inc

Original FDA data

Every field from FDA enforcement report D-0584-2025, exactly as published.

Show all FDA fields
City
Rahway
State
NJ
Status
Ongoing
Country
United States
Event ID
97254
Address
126 E Lincoln Ave
Code information
Lots 2090019 and 2123744, Exp. 4/30/2027
Postal code
07065-4607
Report date
Aug 20, 2025
Product type
Drugs
Recall number
D-0584-2025
Classification
Class II
Recalling firm
Merck & Co. Inc
Product quantity
51,320 cartons
Reason for recall
Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label)
Distribution pattern
Nationwide in the USA and PR.
Recall initiation date
Jul 21, 2025
Center classification date
Aug 13, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0584-2025, published Aug 20, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls